Therapeutic Response

PDGFRA p.D842V status confers therapeutic sensitivity to Avapritinib in patients with Gastrointestinal Stromal Tumor.

Statements

Source and description
Ayvakyt (avapritinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.
Ayvakit (avapritinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.